The steroid receptor RNA activator gene (SRA1) generates two distinct entities. SRA RNA coactivates several NRs whereas SRA protein (SRAP) is suspected to regulate the activity of several transcription factors, including estrogen receptors (ER). Splicing of SRA intron-1 is the major event defining SRAP coding frame. Fully spliced, coding SRA and intron-1 retained, non-coding SRA coexist in breast cancer cells. The relative proportion between the two types of SRA RNA maintains a balance between two genetically linked entities, SRA and SRAP. In this study, a minigene model was used to demonstrate that the primary sequence of SRA exon-1-intron-1-exon-2 is sufficient for alternative splicing of SRA intron-1. In addition, a modified oligoribonucleotidic construct promotes SRA intron-1 retention in breast cancer cells. This oligoribonucleotide differentially alters estradiol-induced transcription of ER regulated genes. Together, results presented herein demonstrate that the SRA-SRAP balance, which can be artificially modified by targeting alternative splicing of SRA intron-1, might be a new critical target to treat breast cancer patients.

The steroid receptor RNA activator gene (SRA1) generates two distinct entities. SRA RNA coactivates several NRs whereas SRA protein (SRAP) is suspected to regulate the activity of several transcription factors, including estrogen receptors (ER). Splicing of SRA intron-1 is the major event defining SRAP coding frame. Fully spliced, coding SRA and intron-1 retained, non-coding SRA coexist in breast cancer cells. The relative proportion between the two types of SRA RNA maintains a balance between two genetically linked entities, SRA and SRAP. In this study, a minigene model was used to demonstrate that the primary sequence of SRA exon-1-intron-1-exon-2 is sufficient for alternative splicing of SRA intron-1. In addition, a modified oligoribonucleotidic construct promotes SRA intron-1 retention in breast cancer cells. This oligoribonucleotide differentially alters estradiol-induced transcription of ER regulated genes. Together, results presented herein demonstrate that the SRA-SRAP balance, which can be artificially modified by targeting alternative splicing of SRA intron-1, might be a new critical target to treat breast cancer patients.

Abstract The hormonally active form of vitamin D, 1,25(OH)2D3, is involved in many biological functions throughout the body, such as regulation of calcium and phosphate homeostasis, bone remodeling and controlling cell proliferation and differentiation. Vitamin D receptor (VDR), a member of the nuclear hormone receptor (NHR) super family, mediates those genomic actions of 1,25 (OH)2D3 by actively repressing or activating its target genes. In the present study recombinant human nuclear VDR and its ligand binding domain (LBD) were expressed in Spodoptera frugiperda (Sf9) insect cells and in E.coli. Recombinant proteins were purified and their biochemical and biophysical properties were characterized. Recombinant VDR was shown to bind to the vitamin D response element (VDRE) of osteopontin and osteocalcin genes as a homodimer or as a heterodimer with the retinoid X receptor (RXR)-αΔAB. Full-length VDR and its LBD were demonstrated to bind natural ligand 1,25 (OH)2D3 with high affinity. The binding affinities of several vitamin D analogs were also determined. Ligand binding induced conformational change within the receptor was studied using several methods such as partial proteolytic digestion, small angle neutron scattering (SANS), native gel electrophoresis and circular dichroism (CD) spectroscopy. Results indicate that ligand binding induces conformational change within VDR and different 1,25(OH)2D3 analogs might induce a somewhat different conformation within the receptor. This is seen as an unequal capacity of analogs to stabilize receptor against proteases or heat and as differences in the promotion of receptor homodimerization. Compared to other nuclear hormone receptors, VDR presents a large insertion region at the N-terminal part of the LBD between helices H1 and H3, encoded by an additional exon. In the present study this additional exon was deleted and the properties of mutated LBD were compared to the wild type LBD. Biochemical analyses indicated that the mutant protein exhibits the same ligand binding, dimerization with RXR and transactivation properties as the wild-type VDR, suggesting that the insertion region does not affect these main functions. Furthermore, solution studies by small angle X-ray scattering indicated that the insertion region in the VDR locates on the surface of molecule and it is not structurally well ordered.

Der Gelbkörper (corpus luteum, CL) ist eine transitorische Drüse, die im Ovar nach der Ovulation gebildet wird und durch ihre Progesteron-(P4)-Produktion die Trächtigkeit unterstützt. Bei allen bisher untersuchten Säugetieren endet die sekretorische Aktivität der CL mit dem Ende der Trächtigkeit oder Laktation, danach werden die CL abgebaut. Der Zyklus von Katzenartigen, wie etwa der Hauskatze, folgt dem gleichen Muster. Anders verläuft der Zyklus bei Luchsen. Beim Eurasischen Luchs (Lynx lynx) und beim Pardelluchs (Lynx pardinus) persistieren die CL nach der Geburt für mehr als zwei Jahre und sezernieren weiter P4. Die vorgestellte Arbeit sollte die Funktion persistierender (per) CL im Luchs untersuchen und die Fortpflanzung von Katzen weiter aufklären. Dazu wurden grundlegende histologische und hormonelle Aspekte der Lutealphase analysiert und der Einfluss des apoptotischen Systems sowie die Rezeptivität gegenüber Steroiden bei der Regulation der CL-Funktion betrachtet. Die CL von Hauskatzen und Luchsen wurden histomorphologisch unterteilt. In allen Proben wurden intraluteales P4 und Östrogene bestimmt. Weiterhin wurde die mRNA- und, wenn möglich, die Proteinexpression der proapoptotischen Faktoren BAX, Caspase-3, FAS, Tumor necrosis factor (TNF), TNF Rezeptor 1 (TNFRSFA1) und der Überlebensfaktoren (BCL2, TNFRSFB1), sowie des Progesteronrezeptors (PGR), der PGR-Membrankomponente (PGRMC) 1 und 2, des Östrogenrezeptors (ESR) 1 und 2, des G-Protein-gekoppelten Östrogenrezeptors 1 (GPER1) und des Androgenrezeptors (AR) gemessen. Die Ergebnisse weisen darauf hin, dass die Lutealphase der Hauskatze durch FAS, Caspase-3 und die TNF Rezeptoren 1 und 2 reguliert sein könnte. Steroide könnten über ihre Rezeptoren PGR, PGRMC1 und PGRMC2, ESR1 und AR wirken. Die physiologische Persistenz der CL beim Luchs könnte über BCL2, FAS, TNFRSFB1, PGRMC1, PGRMC2, ESR1, GPER1 und AR vermittelt werden. / Corpus luteum (CL) is a transitory gland which forms in the ovary after ovulation and supports the pregnancy with its production of progesterone (P4). In all mammals studied so far, the CL loses its secretory activity after pregnancy and regresses from the ovary. The feline luteal cycle follows the same pattern, and CL of the domestic cat functionally and structurally regress after lactation. However, the story is different for the lynx. In the Eurasian (Lynx lynx) and Iberian (Lynx pardinus) lynx, CL persist after parturition, weaning and for up to two years, still retaining their ability to secrete P4. Current work was initiated to understand the control of unusual persistent (per) CL in lynx and to learn more about feline reproduction in general. For this, studies on the basic histological and endocrinological aspects of the feline luteal phase, as well as potential involvement of systems of apoptosis and steroid receptivity in the CL regulation were performed. Collected CL from domestic cats and lynx were classified based on their histomorphology. In all samples, intraluteal P4 and estrogens were measured. Moreover, mRNA and where possible protein levels were determined for pro-apoptotic BAX, caspase-3, FAS, tumor necrosis factor (TNF), TNF receptor 1 (TNFRSFA1), pro-survival BCL2, TNFRSFB1, and for progesterone receptor (PGR), PGR membrane components (PGRMC) 1 and 2, estrogen receptors (ESR) 1 and 2, G protein-coupled estrogen receptor 1 (GPER1) and androgen receptor (AR). The results suggest that the luteal phase of the domestic cat is potentially regulated by caspase-3, FAS, TNFRSF1A, TNFRSF1B, and by actions of steroids via PGR, PGRMC1, PGRMC2, ESR1 and AR. Physiological persistence of Iberian lynx CL might be mediated by BCL2, FAS, TNFRSFB1, PGRMC1, PGRMC2, ESR1, GPER1 and AR. Current work indicates profound differences between the CL function and regulation in domestic cats and lynx, and promotes a highly species-specific approach in reproduction studies.

O câncer de mama é o carcinoma que mais acomete mulheres no Brasil. Os tratamentos disponíveis são recomendados a partir da análise de fatores de prognóstico como a classificação pelo sistema TNM, tipo histológico, status de receptores hormonais e marcadores de proliferação tumoral. No entanto, a classificação dos tumores de mama é muito variável e o poder prognóstico dos marcadores tumorais atuais ainda é limitado, levando muitas pacientes à terapia adjuvante desnecessária. Portanto, novos métodos de prognóstico mais sensíveis são necessários para melhorar a tomada de decisão na clínica oncológica de pacientes com câncer de mama. Do ponto de vista de ciência básica, as modificações transcricionais associadas à oncogênese e progressão do câncer de mama ainda são pouco conhecidas. Além da alteração na expressão de genes codificadores para proteínas, evidências recentes sugerem que RNAs não-codificadores (ncRNAs) podem ter um papel importante na transformação maligna. Este projeto teve como principais objetivos: i) investigar a expressão de ncRNAs intrônicos em amostras de adenocarcinoma de mama e ii) identificar assinaturas de expressão gênica associadas a características anatomo-patológicas e clínicas de tumores de mama com potencial aplicação clínica. Para isso, foram comparados os perfis de expressão gênica de 58 amostras de tecido tumoral de mama, com seguimento clínico conhecido, utilizando uma plataforma de microarranjos de cDNA, enriquecida em ncRNAs provenientes de regiões intrônicas de genes humanos conhecidos. 9 Durante o projeto foram testadas diferentes metodologias para análise da expressão gênica utilizando microarranjos de cDNA com uma ou duas cores. O desenho experimental das hibridizações incluiu a co-hibridização de cada microarranjo com alvos fluorescentes representando o transcritoma da amostra de tumor juntamente com um oligonucleotídeo referência complementar a uma região presente em todas as sondas de cDNA (RefOligo). Este desenho experimental permitiu a avaliação de duas abordagens de análise da expressão gênica: a primeira baseada nas intensidades diretas de cada transcrito (One-Color) e a segunda baseada em razões de expressão onde a intensidade de cada transcrito foi normalizada pelo oligonucleotídeo referência (RefOligo). A utilização direta das intensidades se mostrou mais reprodutível e sensível para a detecção de assinaturas de expressão correlacionadas com características das amostras de mama, e essa abordagem foi escolhida para as análises subseqüentes. Os dados provenientes dos experimentos de microarranjos revelaram níveis de expressão ubíqüos dos transcritos intrônicos nas amostras analisadas, extendendo para o câncer de mama a relevância do estudo desta classe de ncRNAs. Além disso, foi identificada uma assinatura contendo 95 transcritos, correlacionada com o status de expressão do receptor de estrogênio (REr), dos quais cerca de 15% correspondem a ncRNAs. Utilizando apenas amostras com seguimento clínico superior a 4 anos, foi identificada uma assinatura com 113 transcritos, dos quais cerca de 30% são ncRNAs intrônicos, capaz de distinguir com 100% de acurácia pacientes que desenvolveram metástase daqueles que permaneceram livres da doença. Além de contribuir com novos candidatos a marcadores de prognóstico no câncer de mama, este estudo aponta para a participação de ncRNAs intrônicos em complexas redes transcricionais, possivelmente modulando a expressão de genes codificadores para proteínas. A caracterização detalhada da função de ncRNAs com expressão correlacionada a características fenotípicas e clínicas dos tumores de mama deverá fornecer novas informações sobre as bases moleculares da tumorigênese e progressão desta neoplasia. / Breast carcinoma is the most frequently occurring cancer amongst women in Brazil. The treatments available for breast cancer are prescribed based on the results of prognostic factors, such as the TNM classification system, histological type, hormonal receptor status and tumoral markers for cell proliferation. Nevertheless, breast cancer classification can be variable and inconsistent, and the prognosis power of tumoral markers is still limited, resulting in many patients unnecessarily undergoing adjuvant therapy. Therefore, there is an urge for new prognosis methods that are more sensitive, as well as accurate, in order to improve treatment decisions for breast cancer patients. From a basic science perspective, transcriptional modifications associated with oncogenesis and breast cancer progression are still poorly understood. Beyond alterations of the expression of protein-coding genes, recent evidences suggest that non-coding RNAs (ncRNAs) might have an important role in malignant transformation. The main goals of this project are: i) to investigate the expression of intronic ncRNAs in breast cancer tissue and ii) to identify gene expression signatures correlated to anatomo-pathological and clinical characteristics of human breast tumors, with a potential clinical aplication. To achieve this, gene expression profiles of 58 breast tumor samples with clinical follow-up were compared using a microarray platform enriched in non-coding RNAs (ncRNAs) derived from intronic regions of known human genes. During this project different gene expression methodologies were tested for the analysis of one- or two-color cDNA microarrays. The experimental design included the co-hybridization of the microarrays with fluorescent targets representing the tumor sample transcriptome with a reference oligonucleotide that is complementary to a 12 common region present in all cDNA probes (RefOligo). This experimental design permited the evaluation of two gene expression analysis approaches: the first based on direct intensities of each transcript (One-Color) and the second based in expression ratios where the intensity of each transcript is normalized by the reference oligonucleotide (RefOligo). One-Color methodology has shown to provide a more reproducible and sensitive gene expression signatures correlated to the breast samples characteristics and, therefore, this approach was chosen for subsequent analysis. The data provided by the microarray experiments revealed that ubiquitous expression of intronic ncRNAs was observed, confirming the relevance of investigating the role of this class of ncRNAs in breast cancer. Furthermore, a gene expression signature comprising 95 transcripts and correlated to the estrogen receptor status of breast tumor samples was identified, from which approximately 15% are ncRNAs. Using only samples from patients with known follow-up, a signature of 113 transcripts was identified, of which 30% are ncRNAs. This gene expression signature was able to distinguish with 100% accuracy patients that developed metastasis from those that remained disease-free up to 4 years after surgery. Besides the contribution of new molecular prognostic markers for breast cancer, the present study indicates that intronic ncRNAs might play a role in complex transcriptional networks, possibly regulating the expression of protein-coding genes. The detailed caracterization of the functional roles of ncRNAs, whose expression levels are correlated to fenotypical and clinical characteristics of breast tumors, is likely to provide new insigths on the molecular basis of tumorigenesis and progression of this neoplasia.

O câncer de mama é o carcinoma que mais acomete mulheres no Brasil. Os tratamentos disponíveis são recomendados a partir da análise de fatores de prognóstico como a classificação pelo sistema TNM, tipo histológico, status de receptores hormonais e marcadores de proliferação tumoral. No entanto, a classificação dos tumores de mama é muito variável e o poder prognóstico dos marcadores tumorais atuais ainda é limitado, levando muitas pacientes à terapia adjuvante desnecessária. Portanto, novos métodos de prognóstico mais sensíveis são necessários para melhorar a tomada de decisão na clínica oncológica de pacientes com câncer de mama. Do ponto de vista de ciência básica, as modificações transcricionais associadas à oncogênese e progressão do câncer de mama ainda são pouco conhecidas. Além da alteração na expressão de genes codificadores para proteínas, evidências recentes sugerem que RNAs não-codificadores (ncRNAs) podem ter um papel importante na transformação maligna. Este projeto teve como principais objetivos: i) investigar a expressão de ncRNAs intrônicos em amostras de adenocarcinoma de mama e ii) identificar assinaturas de expressão gênica associadas a características anatomo-patológicas e clínicas de tumores de mama com potencial aplicação clínica. Para isso, foram comparados os perfis de expressão gênica de 58 amostras de tecido tumoral de mama, com seguimento clínico conhecido, utilizando uma plataforma de microarranjos de cDNA, enriquecida em ncRNAs provenientes de regiões intrônicas de genes humanos conhecidos. 9 Durante o projeto foram testadas diferentes metodologias para análise da expressão gênica utilizando microarranjos de cDNA com uma ou duas cores. O desenho experimental das hibridizações incluiu a co-hibridização de cada microarranjo com alvos fluorescentes representando o transcritoma da amostra de tumor juntamente com um oligonucleotídeo referência complementar a uma região presente em todas as sondas de cDNA (RefOligo). Este desenho experimental permitiu a avaliação de duas abordagens de análise da expressão gênica: a primeira baseada nas intensidades diretas de cada transcrito (One-Color) e a segunda baseada em razões de expressão onde a intensidade de cada transcrito foi normalizada pelo oligonucleotídeo referência (RefOligo). A utilização direta das intensidades se mostrou mais reprodutível e sensível para a detecção de assinaturas de expressão correlacionadas com características das amostras de mama, e essa abordagem foi escolhida para as análises subseqüentes. Os dados provenientes dos experimentos de microarranjos revelaram níveis de expressão ubíqüos dos transcritos intrônicos nas amostras analisadas, extendendo para o câncer de mama a relevância do estudo desta classe de ncRNAs. Além disso, foi identificada uma assinatura contendo 95 transcritos, correlacionada com o status de expressão do receptor de estrogênio (REr), dos quais cerca de 15% correspondem a ncRNAs. Utilizando apenas amostras com seguimento clínico superior a 4 anos, foi identificada uma assinatura com 113 transcritos, dos quais cerca de 30% são ncRNAs intrônicos, capaz de distinguir com 100% de acurácia pacientes que desenvolveram metástase daqueles que permaneceram livres da doença. Além de contribuir com novos candidatos a marcadores de prognóstico no câncer de mama, este estudo aponta para a participação de ncRNAs intrônicos em complexas redes transcricionais, possivelmente modulando a expressão de genes codificadores para proteínas. A caracterização detalhada da função de ncRNAs com expressão correlacionada a características fenotípicas e clínicas dos tumores de mama deverá fornecer novas informações sobre as bases moleculares da tumorigênese e progressão desta neoplasia. / Breast carcinoma is the most frequently occurring cancer amongst women in Brazil. The treatments available for breast cancer are prescribed based on the results of prognostic factors, such as the TNM classification system, histological type, hormonal receptor status and tumoral markers for cell proliferation. Nevertheless, breast cancer classification can be variable and inconsistent, and the prognosis power of tumoral markers is still limited, resulting in many patients unnecessarily undergoing adjuvant therapy. Therefore, there is an urge for new prognosis methods that are more sensitive, as well as accurate, in order to improve treatment decisions for breast cancer patients. From a basic science perspective, transcriptional modifications associated with oncogenesis and breast cancer progression are still poorly understood. Beyond alterations of the expression of protein-coding genes, recent evidences suggest that non-coding RNAs (ncRNAs) might have an important role in malignant transformation. The main goals of this project are: i) to investigate the expression of intronic ncRNAs in breast cancer tissue and ii) to identify gene expression signatures correlated to anatomo-pathological and clinical characteristics of human breast tumors, with a potential clinical aplication. To achieve this, gene expression profiles of 58 breast tumor samples with clinical follow-up were compared using a microarray platform enriched in non-coding RNAs (ncRNAs) derived from intronic regions of known human genes. During this project different gene expression methodologies were tested for the analysis of one- or two-color cDNA microarrays. The experimental design included the co-hybridization of the microarrays with fluorescent targets representing the tumor sample transcriptome with a reference oligonucleotide that is complementary to a 12 common region present in all cDNA probes (RefOligo). This experimental design permited the evaluation of two gene expression analysis approaches: the first based on direct intensities of each transcript (One-Color) and the second based in expression ratios where the intensity of each transcript is normalized by the reference oligonucleotide (RefOligo). One-Color methodology has shown to provide a more reproducible and sensitive gene expression signatures correlated to the breast samples characteristics and, therefore, this approach was chosen for subsequent analysis. The data provided by the microarray experiments revealed that ubiquitous expression of intronic ncRNAs was observed, confirming the relevance of investigating the role of this class of ncRNAs in breast cancer. Furthermore, a gene expression signature comprising 95 transcripts and correlated to the estrogen receptor status of breast tumor samples was identified, from which approximately 15% are ncRNAs. Using only samples from patients with known follow-up, a signature of 113 transcripts was identified, of which 30% are ncRNAs. This gene expression signature was able to distinguish with 100% accuracy patients that developed metastasis from those that remained disease-free up to 4 years after surgery. Besides the contribution of new molecular prognostic markers for breast cancer, the present study indicates that intronic ncRNAs might play a role in complex transcriptional networks, possibly regulating the expression of protein-coding genes. The detailed caracterization of the functional roles of ncRNAs, whose expression levels are correlated to fenotypical and clinical characteristics of breast tumors, is likely to provide new insigths on the molecular basis of tumorigenesis and progression of this neoplasia.